Key result
This editorial discusses the POINT trial, which investigated antiplatelet regimens for the prevention of recurrent stroke in patients after TIA or minor ischemic stroke.
Why the study?
What are the appropriate antiplatelet regimens for the prevention of recurrent stroke in patients after TIA or minor ischemic stroke?
What are the appropriate antiplatelet regimens for the prevention of recurrent stroke in patients after TIA or minor ischemic stroke?
Answers are grounded in this paper and cite their sources.
This editorial discusses the implications of the POINT trial regarding appropriate antiplatelet regimens for preventing recurrent stroke after TIA or minor ischemic stroke.
Antiplatelet therapy is the mainstay for the prevention of primary stroke in patients with risk factors and for the prevention of recurrent stroke after transient ischemic attack (TIA) or ischemic stroke. An outstanding question concerns appropriate antiplatelet regimens under various clinical scenarios. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, the results of which have now been published in the Journal,1 investigated antiplatelet regimens for the prevention of recurrent stroke in patients after TIA or minor stroke, with the latter being defined according to a National Institutes of Health Stroke Scale score of 3 or less . . .
No takes yet. Share an insight, caveat, or question.
James C. Grotta (2018) conducted an editorial in TIA or minor ischemic stroke. Antiplatelet regimens was evaluated on Recurrent stroke. This editorial discusses the POINT trial, which investigated antiplatelet regimens for the prevention of recurrent stroke in patients after TIA or minor ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: